Your browser doesn't support javascript.
loading
Focal injection of a radiopaque viscous spacer before focal brachytherapy as re-irradiation for locally recurrent prostate cancer.
Pinkawa, Michael; Hermani, Horst; Bischoff, Peter; Hanitzsch, Herbert; Heidrich, Albert; Schäfer, Andreas; Kovács, Attila; Haddad, Hathal.
Affiliation
  • Pinkawa M; Department of Radiation Oncology, MediClin Robert Janker Klinik, Bonn, Germany. Electronic address: michael.pinkawa@post.rwth-aachen.de.
  • Hermani H; Department of Radiation Oncology, MediClin Robert Janker Klinik, Bonn, Germany.
  • Bischoff P; Department of Interventional and Diagnostic Radiology and Neuroradiology, MediClin Robert Janker Klinik, Bonn, Germany.
  • Hanitzsch H; Department of Urology, MediClin Robert Janker Klinik, Bonn, Germany; Urologic Centre Bonn, Bonn, Germany.
  • Heidrich A; Department of Urology, MediClin Robert Janker Klinik, Bonn, Germany; Curos Urologic Centre, Wesseling, Germany.
  • Schäfer A; Department of Interventional and Diagnostic Radiology and Neuroradiology, MediClin Robert Janker Klinik, Bonn, Germany.
  • Kovács A; Department of Interventional and Diagnostic Radiology and Neuroradiology, MediClin Robert Janker Klinik, Bonn, Germany.
  • Haddad H; Department of Radiation Oncology, MediClin Robert Janker Klinik, Bonn, Germany.
Brachytherapy ; 21(6): 848-852, 2022.
Article in En | MEDLINE | ID: mdl-36055928
ABSTRACT

PURPOSE:

Close vicinity of the target volume and a sensitive organ may prevent an effective radiotherapy/brachytherapy. A liquid hydrogel spacer cannot be placed well focally in specific small areas or fatty tissue. The purpose of this study was to report the injection technique and results of a radiopaque viscous hydrogel spacer.

METHODS:

The radiopaque viscous spacer was applied focally using transrectal ultrasound guidance before focal brachytherapy in re-irradiated areas in two patients. The technical feasibility of the injection between the recurrence and the rectum / bladder, the resulting distance, visibility in different imaging modalities, stability within several months, dose distribution, toxicity and tumor control up to 18 months after treatment was analyzed.

RESULTS:

After hydrodissection, the needle was moved from the base towards the apex during injection of each syringe, respectively. The viscous spacer could be successfully injected focally and resulted in a planned distancing of the target volume (right lobe and seminal vesicle area) and the rectum of at least 1 cm and additional distancing to the bladder of at least 5 mm. Both brachytherapy treatments were performed without relevant toxicities. The PSA nadirs indicated a satisfactory short-term response to the treatment.

CONCLUSIONS:

The viscous hydrogel spacer can be injected focally at a specific prostate lobe or seminal vesicles. A viscous spacer remains stable within fatty tissue in any areas that are accessible by an ultrasound guided needle injection to create a distance between the high brachytherapy dose within the target and the organ at risk.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Brachytherapy / Re-Irradiation Type of study: Guideline Limits: Humans / Male Language: En Journal: Brachytherapy Journal subject: RADIOTERAPIA Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Brachytherapy / Re-Irradiation Type of study: Guideline Limits: Humans / Male Language: En Journal: Brachytherapy Journal subject: RADIOTERAPIA Year: 2022 Document type: Article